IN THE NEWS

Syros raises $40M to get its leukemia drug into Phase II; FierceBiotech. Garde, Damian.

January 15,  2016

Eyeing First Trials, Syros Brings in $40M and More Crossovers; xConomy. Fidler, Ben.

January 13,  2016

Cambridge's Syros gets $40M to start trials of leukemia dru; Boston Business Journal. Bartlett, Jessica.

January 13,  2016

Investors cheering Syros: RARα agonist to phase II in AML, MDS with $40M; BioWorld. Osbourne, Randy

January 13,  2016

Gene control play Syros raises $40; Biocentury. Cain, Chris

January 13,  2016

Syros Pharmaceuticals Hacking the Genetic Operating Systems; FierceBiotech. Garde, Damian.


September 27,  2015

Pharma gives drug development the Hollywood treatment; The Boston Globe.  Weisman, Robert

September 27, 2015

Biotech’s wellspring—a survey of the health of the private sector in 2014; Nature Biotechnology. Huggett, Brady

May 2015

Five things you should know about Nancy SimonianThe Boston Globe. Weisman, Robert

May 2, 2015

Syros Takes on Super-EnhancersChemical & Engineering News. Jarvis, Lisa

February 23, 2015

Syros Raises $53M More To Push Gene-Control Drugs Into Human Trials Xconomy. Lash, Alex


October 27, 2014

GREECE-ING THE CLINICAL SKIDS Neighborhood watch: Gene maps get 'Syros,' draw $53M series B BioWorld. Osbourne, Randy

October 27, 2014

Selecting CDK7 SCIBX. Can, Chris

July 24, 2014

Nature Biotechnology's academic spinouts of 2013 Nature Biotechnology. Bouchie, Aaron; Allison, Malorye; Webb, Sarah; DeFrancesco

March 10, 2014

Syros: Super maps; BioCentury on BioBusiness.  Cain, Chris

April 15, 2013

Super-powered switches may decide cell fate;  Nature. Maxmen, Amy

April 12, 2013

Syros Pharma snags $30M funding deal to target master switches of cancer genes; FierceBiotech.  McBride, Ryan

April 11, 2013

Syros, a Whitehead and Dana-Farber Spinoff, Snags $30M For Cancer;  Xconomy. Timmerman, Luke

April 11, 2013


Media Contact:

Naomi Aoki | Ten Bridge Communications |617-283-4298 | email: naomi@tenbridgecommunications.com